Format

Send to

Choose Destination
See comment in PubMed Commons below
Support Care Cancer. 2013 Nov;21(11):3233-41. doi: 10.1007/s00520-013-1900-x. Epub 2013 Jul 11.

Emerging evidence on the pathobiology of mucositis.

Author information

1
Discipline of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5000, Australia, noor.al-dasooqi@adelaide.edu.au.

Abstract

BACKGROUND:

Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely.

METHODS:

Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011.

RESULTS:

Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology.

CONCLUSION:

The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.

PMID:
23842598
DOI:
10.1007/s00520-013-1900-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center